top of page

From Montreal: Find Therapeutics is developing transmembrane directed peptides - its initial testing of this platform that could have wide utility is in demyelinating diseases like MS

1 min read

CMO Robert Glanzman describes the platform, which originated at the University of Strasbourg, and why they chose MS as the lead program. They have already tested it in healthy volunteers in phase 1 and are currently preparing for a phase 2 study. Find is an example of a company that has benefited from Montreal's adMare BioInnovations.

https://vimeo.com/1243536093?share=copy&fl=sv&fe=ci

Recent Posts

See All

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

From Montreal: Ocythera is developing a treatment for rare bone disorders that targets the retinoic acid pathway without using retinoids

Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more